Cargando…

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

AIM: To perform a model‐based analysis of the short‐ and long‐term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden. MATERIALS AND METHODS: The validated Institute for Health Economi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilsson, Kristoffer, Andersson, Emelie, Persson, Sofie, Karlsdotter, Kristina, Skogsberg, Josefin, Gustavsson, Staffan, Jendle, Johan, Steen Carlsson, Katarina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107920/ https://www.ncbi.nlm.nih.gov/pubmed/36371543 http://dx.doi.org/10.1111/dom.14921

Ejemplares similares

Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality
por: Persson, Sofie, et al.
Publicado: (2022)

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
por: Bernfort, Lars, et al.
Publicado: (2020)

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
por: Andersson, Emelie, et al.
Publicado: (2020)

Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
por: Bernfort, Lars, et al.
Publicado: (2020)

Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations
por: Lundqvist, Adam, et al.
Publicado: (2014)

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
por: Eliasson, Björn, et al.
Publicado: (2022)

Why childhood-onset type 1 diabetes impacts labour market outcomes: a mediation analysis
por: Persson, Sofie, et al.
Publicado: (2017)

Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes
por: Dwibedi, Chinmay, et al.
Publicado: (2022)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Transcriptional Profiling Uncovers a Network of Cholesterol-Responsive Atherosclerosis Target Genes
por: Skogsberg, Josefin, et al.
Publicado: (2008)

VEGF‐B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content
por: Moessinger, Christine, et al.
Publicado: (2020)

Program budgeting and benefit-cost analysis : cases, text, and readings /
Publicado: (1969)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
por: Deng, Xinru, et al.
Publicado: (2022)

Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study
por: Steen Carlsson, Katarina, et al.
Publicado: (2022)

Benefits of Minimizing the Vertex Detector Material Budget at the FCC-ee
por: Freitag, Leila
Publicado: (2023)

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer
por: Skarping, Ida, et al.
Publicado: (2022)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes”
Publicado: (2022)

Low Incidence of Reinfection With Endemic Coronaviruses Diagnosed by Real-Time PCR
por: Ringlander, Johan, et al.
Publicado: (2020)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4(+) T-Cell Responses
por: Marklund, Emelie, et al.
Publicado: (2021)

Is Glacial Meltwater a Secondary Source of Legacy Contaminants to Arctic Coastal Food Webs?
por: McGovern, Maeve, et al.
Publicado: (2022)

IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections
por: Rugwizangoga, Belson, et al.
Publicado: (2019)

Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes
por: Matsumura, Takeshi, et al.
Publicado: (2022)

Establishing a Low-Budget Hysteroscopy Unit in a Resource-Poor Setting
por: Okohue, Jude Ehiabhi, et al.
Publicado: (2020)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer
por: Taflin, Helena, et al.
Publicado: (2018)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)

The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience
por: Bidiuk, Joanna, et al.
Publicado: (2022)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d16f17a9cki8f4ogtapfujc27f